ClinVar Miner

Submissions for variant NM_000051.4(ATM):c.6975G>A (p.Ala2325=) (rs556778314)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000130288 SCV000185135 likely benign Hereditary cancer-predisposing syndrome 2019-10-11 criteria provided, single submitter clinical testing RNA Studies
Invitae RCV000196388 SCV000254137 uncertain significance Ataxia-telangiectasia syndrome 2020-01-06 criteria provided, single submitter clinical testing This sequence change affects codon 2325 of the ATM mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the ATM protein. This variant also falls at the last nucleotide of exon 47 of the ATM coding sequence, which is part of the consensus splice site for this exon. This variant is present in population databases (rs556778314, ExAC 0.009%). This variant has not been reported in the literature in individuals with ATM-related disease. ClinVar contains an entry for this variant (Variation ID: 141676). Nucleotide substitutions within the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
GeneDx RCV000679141 SCV000292477 uncertain significance not provided 2018-11-09 criteria provided, single submitter clinical testing This variant is denoted ATM c.6975G>A at the DNA level. It is silent at the coding level, preserving an Alanine at codon 2325. In silico analyses, which include splice predictors and evolutionary conservation, are uninformative in their assessment as to whether or not the variant is damaging. This variant was reported in 2/13,087 cases and 2/5,488 controls in a breast cancer case-control study (Decker 2017). ATM c.6975G>A was not observed at a significant allele frequency in large population cohorts (Lek 2016). Based on currently available evidence, it is unclear whether ATM c.6975G>A is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Color Health, Inc RCV000130288 SCV000537558 uncertain significance Hereditary cancer-predisposing syndrome 2020-02-21 criteria provided, single submitter clinical testing
PreventionGenetics,PreventionGenetics RCV000679141 SCV000805610 uncertain significance not provided 2017-09-01 criteria provided, single submitter clinical testing
Mendelics RCV000196388 SCV001138556 likely pathogenic Ataxia-telangiectasia syndrome 2019-05-28 criteria provided, single submitter clinical testing
Athena Diagnostics Inc RCV000679141 SCV001475568 uncertain significance not provided 2019-12-27 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.